Gene

Genetic enhancement

Intensive care medicine

Biology

Cell therapy

Stem cell

Biochemistry

Hematopoietic stem cell transplantation

Immunology

Genetics

Immune system

Graft-versus-host disease

Internal medicine

Immunopathology

Medicine

Immunotherapy

Disease

Frontiers in Immunology

Graft versus host disease (GVHD) is one of the main causes of mortality and the reason for up to 50% of morbidity after hematopoietic stem cell transplantations (HSCT) which is the treatment of choice for many blood malignancies. Thanks to years of research and exploration, we have acquired a profound understanding of the pathophysiology and immunopathology of these disorders. This led to the proposition and development of many therapeutic approaches during the last decades, some of them with very promising results. In this review, we have focused on the recent GVHD treatments from classical chemical and pharmacological prophylaxis to more innovative treatments including gene therapy and cell therapy, most commonly based on the application of a variety of immunomodulatory cells. Furthermore, we have discussed the advantages and potentials of cell-free therapy as a newly emerging approach to treat GVHD. Among them, we have particularly focused on the implication of the TNFα-TNFR2 axis as a new immune checkpoint signaling pathway controlling different aspects of many immunoregulatory cells.

Current Preventions and Treatments of aGVHD: From Pharmacological Prophylaxis to Innovative Therapies